Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

about

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

Item

http://www.wikidata.org/entity/Q39941690

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

@en

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

@nl

type

Item

label

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

@en

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

@nl

prefLabel

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

@en

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

@nl

P1476

Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.

@en

P2093

Robert P Frantz

http://www.w3.org/2001/XMLSchema#string

P2860

Management of pulmonary arterial hypertension with a focus on combination therapies.

Survival with first-line bosentan in patients with primary pulmonary hypertension.

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

Clinical trials in systemic sclerosis: lessons learned and outcomes.

Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

P304

459-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14796678.4.5.459

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19804340

http://www.w3.org/2001/XMLSchema#string